Curcumin and nano-curcumin applications in psychiatric disorders

被引:0
|
作者
Mohammadzadeh, R. [1 ]
Fathi, M. [1 ]
Pourseif, M. M. [1 ]
Omidi, Y. [2 ]
Farhang, S. [3 ]
Jalali, M. Barzegar [1 ]
Valizadeh, H. [1 ]
Nakhlband, A. [3 ]
Adibkia, K. [1 ]
机构
[1] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
[2] Nova Southeastern Univ, Coll Pharm, Dept Pharmaceut Sci, Ft Lauderdale, FL USA
[3] Tabriz Univ Med Sci, Razi Psychiat Hosp, Res Ctr Psychiat & Behav Sci, Elgoli St,Block 2, Tabriz 5971919143, Iran
关键词
curcumin; nanocurcumin; psychiatric disorders; NF-KAPPA-B; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; BIPOLAR DISORDER; DOUBLE-BLIND; MAJOR DEPRESSION; AMYLOID-BETA; IN-VITRO; BRAIN; SCHIZOPHRENIA;
D O I
10.1002/ptr.8265
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Psychiatric disorders cause long-lasting disabilities across different age groups. While various medications are available for mental disorders, some patients do not fully benefit from them or experience treatment resistance. The pathogenesis of psychiatric disorders involves multiple mechanisms, including an increase in the inflammatory response. Targeting inflammatory mechanisms has shown promise as a therapeutic approach for these disorders. Curcumin, known for its anti-inflammatory properties and potential neuroprotective effects, has been the subject of studies investigating its potential as a treatment option for psychiatric disorders. This review comprehensively examines the potential therapeutic role of curcumin and its nanoformulations in psychiatric conditions, including major depressive disorder (MDD), bipolar disorder, schizophrenia, and anxiety disorders. There is lack of robust clinical trials across all the studied psychiatric disorders, particularly bipolar disorder and schizophrenia. More studies have focused on MDD. Studies on depression indicate that curcumin may be effective as an antidepressant agent, either alone or as an adjunct therapy. However, inconsistencies exist among study findings, highlighting the need for further research with improved blinding, optimized dosages, and treatment durations. Limited evidence supports the use of curcumin for bipolar disorder, making its therapeutic application challenging. Well-designed clinical trials are warranted to explore its potential therapeutic benefits. Exploring various formulations and delivery strategies, such as utilizing liposomes and nanoparticles, presents intriguing avenues for future research. More extensive clinical trials are needed to assess the efficacy of curcumin as a standalone or adjunctive treatment for psychiatric disorders, focusing on optimal dosages, formulations, and treatment durations. Curcumin and nano-curcumin applications for psychiatric disorders. image
引用
收藏
页码:4240 / 4260
页数:21
相关论文
共 50 条
  • [41] Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response
    Milano, Francesca
    Mari, Luigi
    van de Luijtgaarden, Wendy
    Parikh, Kaushal
    Calpe, Silvia
    Krishnadath, Kausilia K.
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [42] Comparative effects of curcumin versus nano-curcumin on histological, immunohistochemical expression, histomorphometric, and biochemical changes to pancreatic beta cells and lipid profile of streptozocin induced diabetes in male Sprague–Dawley rats
    Mohamed R. Metawea
    Heba M. A. Abdelrazek
    Heba Nageh Gad El-Hak
    Mona M. Moghazee
    Ohoud M. Marie
    Environmental Science and Pollution Research, 2023, 30 : 62067 - 62079
  • [43] The effect of Nano-curcumin on migraine attacks: A systematic review and meta-analysis of randomized control trials
    Aletaha, Reza
    Kashtkar, Mahsa
    Farshi, Haleh
    Cheraghi, Maryam
    Sanaie, Sarvin
    Ghassab-Abdollahi, Nafiseh
    ADVANCES IN INTEGRATIVE MEDICINE, 2025, 12 (01) : 7 - 12
  • [44] The effectiveness of nano-curcumin on patients with COVID-19: A systematic review of clinical trials
    Shojaei, Mehrnaz
    Foshati, Sahar
    Abdi, Mohaddese
    Askari, Gholamreza
    Sukhorukov, Vasily N.
    Bagherniya, Mohammad
    Sahebkar, Amirhossein
    PHYTOTHERAPY RESEARCH, 2023, 37 (04) : 1663 - 1677
  • [45] Curcumin in epilepsy disorders
    Dhir, Ashish
    PHYTOTHERAPY RESEARCH, 2018, 32 (10) : 1865 - 1875
  • [46] Comparative effects of curcumin versus nano-curcumin on histological, immunohistochemical expression, histomorphometric, and biochemical changes to pancreatic beta cells and lipid profile of streptozocin induced diabetes in male Sprague-Dawley rats
    Metawea, Mohamed R.
    Abdelrazek, Heba M. A.
    El-Hak, Heba Nageh Gad
    Moghazee, Mona M.
    Marie, Ohoud M.
    ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2023, 30 (22) : 62067 - 62079
  • [47] Nano-curcumin: A potential herbal alternative with enhanced anti-E. gingivalis efficacy
    Ramesh, Kumar
    Samander, Kaushik
    Suman
    RESEARCH JOURNAL OF BIOTECHNOLOGY, 2021, 16 (05): : 51 - 56
  • [48] Microbial fermentation-based synthesis of nano-curcumin suggesting the role of pullulan in nano-formulation
    Katiyar, Sheetal
    Srivastava, Nandita
    Choudhury, Anirban Roy
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 265
  • [49] Comparative Effects of Curcumin versus Nano-Curcumin on Insulin Resistance, Serum Levels of Apelin and Lipid Profile in Type 2 Diabetic Rats
    Shamsi-Goushki, Ali
    Mortazavi, Zinat
    Mirshekar, Mohammad Ali
    Mohammadi, Mahdi
    Moradi-Kor, Nasroallah
    Jafari-Maskouni, Saber
    Shahraki, Mansour
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 2337 - 2346
  • [50] Evaluation of the effects of nano-curcumin on the expression of genes involved in biofilm formation in Staphylococcus epidermidis
    Shivaee, Ali
    Meskini, Maryam
    Roodaki, Rojin Rahimi Nejad
    Kalani, Behroz Sadeghi
    Mirshekar, Maryam
    Razavi, Shabnam
    GENE REPORTS, 2021, 23